Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Financing Activities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Cash from Financing Activities for 16 consecutive years, with -$5.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 1.4% to -$5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.6 million through Dec 2025, up 17.11% year-over-year, with the annual reading at -$10.6 million for FY2025, 17.11% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$5.3 million at Anika Therapeutics, down from -$13000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $667000.0 in Q4 2022, with the low at -$7.0 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is -$2.1 million, with a median of -$986500.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities skyrocketed 1011.67% in 2022, then tumbled 10645.65% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $60000.0 in 2021, then surged by 1011.67% to $667000.0 in 2022, then crashed by 48.73% to $342000.0 in 2023, then tumbled by 1665.5% to -$5.4 million in 2024, then grew by 1.4% to -$5.3 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$5.3 million, -$13000.0, and $179000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.